Program
follitropin alfa
Also written as “Gonal-f”, “Follitropin alfa (Primapur)” and “Gonal-f®”.
Its studies are mostly in Infertility · Infertility, Female · Hypogonadism · Anovulation, led by 10 companies.
Drug pageFollitropin alfa: every studyMany companies study it; this page follows only the 23 they lead. All 49 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germany | 131 open or running | phase 4since Nov 4, 2005 | Nov 4, 2005 | Sep 30, 2027phase 3 · NCT07340827 |
| IVFarmaits history only | 20 open or running | phase 3since Mar 2, 2017 | Mar 2, 2017 | none ahead |
| Bharat Serums and Vaccinesits history only | 11 open or running | phase 3since Jan 23, 2022 | Jan 23, 2022 | none ahead |
| Changchun GeneScience Pharmaceuticalits history only | 10 open or running | phase 3since Jan 5, 2015 | Jan 5, 2015 | none ahead |
| Fertility Biotechits history only | 10 open or running | phase 1since May 19, 2015 | May 19, 2015 | none ahead |
| Finoxits history only | 10 open or running | phase 3since May 10, 2010 | May 10, 2010 | none ahead |
| Gema Biotechits history only | 10 open or running | phase 3since May 22, 2015 | May 22, 2015 | none ahead |
| IBSA Institut Biochimiqueits history only | 10 open or running | phase 3since Sep 15, 2006 | Sep 15, 2006 | none ahead |
| MinaPharm Pharmaceuticalsits history only | 10 open or running | phase 4since Nov 30, 2016 | Nov 30, 2016 | none ahead |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 1since Mar 4, 2025 | Mar 4, 2025 | none ahead |
Also a collaborator on its studies: Merck Serono Middle East FZ, Merck Serono GmbH, Germany, Merck Serono Co., Ltd., Japan and Merck Serono S.P.A., Italy.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 4, 2005First study: phase 4 study in InfertilityFirst studyNCT00249834 · 166 enrolled · France
- Jan 22, 2009Phase 4 study in InfertilityNCT00829244 · 200 enrolled · Switzerland
- Feb 18, 20102 phase 3 studiesNCT01071200, NCT01081639
- Mar 4, 2010Phase 4 study in InfertilityNCT01081626 · 310 enrolled · Kuwait, Lebanon, Saudi Arabia
- Aug 11, 20102 phase 3 studies in InfertilityNCT01185782, NCT01183143
- Dec 20, 2011Phase 3 study in InfertilityNCT01497197 · 174 enrolled · United Arab Emirates
- Jun 4, 2013Phase 4 study in InfertilityNCT01871532 · 24 enrolled · Ireland, United Kingdom
- May 19, 2021Phase 1 study in InfertilityNCT04899193 · 72 enrolled · China
- Jul 15, 2025Phase 1 study in HypogonadismNCT07097259 · 55 enrolled · United States
- Nov 17, 2025Phase 1 study in InfertilityNCT07269327 · 24 enrolled · United Kingdom
- Jan 6, 2026Phase 3 study in InfertilityNCT07340827 · 266 planned · Japan
Ahead
- Sep 30, 2027Primary completion: phase 3 study in InfertilityNCT07340827
TargetBeta
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule
Other programs on FSHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Follicle Stimulating Hormonerule | glycotope-gmbh | phase 4 | 6 |
| follitropin deltarule | Ferring Pharmaceuticals | phase 3 | 18 |
Studies
All 13 Merck KGaA, Darmstadt, Germany leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07340827Infertility · Japan | 3 | Recruiting | Sep 30, 2027 | 266 |
| NCT07269327Infertility · United Kingdom | 1 | Completed | Mar 9, 2026 | 24 |
| NCT07097259Hypogonadism · United States | 1 | Completed | Dec 23, 2025 | 55 |
| NCT04899193Infertility · China | 1 | Completed | May 28, 2022 | 72 |
| NCT01871532Infertility · Ireland, United Kingdom | 4 | Terminated | Mar 2014 | 24 |
| NCT01497197Infertility · United Arab Emirates | 3 | Terminated | Jan 2014 | 174 |
| NCT01183143Infertility · Germany | 3 | Completed | Mar 2, 2006 | 215 |
| NCT01185782Infertility · Japan | 3 | Completed | Dec 2007 | 300 |
| NCT01081626Infertility · Kuwait, Lebanon, Saudi Arabia | 4 | Completed | Mar 2011 | 310 |
| NCT01081639Infertility | 3 | Completed | Sep 2004 | 34 |
| NCT01071200Helping Behavior · Italy | 3 | Terminated | Apr 2009 | 133 |
| NCT00829244Infertility · Switzerland | 4 | Completed | Jan 2010 | 200 |
| NCT00249834Infertility · France | 4 | Completed | Jan 16, 2006 | 166 |
How it is read
Names in the registry
- “Gonal-f”, 2 entries
- “Follitropin alfa (Primapur)”, 2 entries
- “Gonal-f®”, 2 entries
- “GONAL-f®”, 2 entries
- “GONAL f® prefilled pen”, 2 entries
Conditions, from the studies’ own filings
- Infertility, 15 studies
- Infertility, Female, 5 studies
- Hypogonadism, 1 study
- Anovulation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.